Expanded access statement for APN-1607

On May 8, 2024, the FDA granted Aprinoia Therapeutics (Aprinoia), headquartered in Cambridge, MA, fast track designation to APN-1607, a Positron Emission Tomography (PET) tracer for imaging tau protein in patients with suspected progressive supranuclear palsy (PSP).  At this time, Aprinoia does not offer expanded access to APN-1607 as a diagnostic agent for PSP. Aprinoia will update the status regarding expanded access should it change.  For further questions about APN-1607 or the status of the Phase 3 PSP trial, please contact Bradford Navia, MD, PhD , Chief Medical Officer,  email: bnavia@aprinoia.com. Further Information about APN-1607 or Aprinoia Therapeutics can be found at the following link: https://aprinoia.com/.